The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019

Imagem de Miniatura
Arquivos
art_KHANH_The_global_burden_of_cancer_attributable_to_risk_2022.PDF (3.86 MB)
Citações na Scopus
304
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
Khanh Bao Tran
LANG, Justin J.
COMPTON, Kelly
XU, Rixing
ACHESON, Alistair R.
HENRIKSON, Hannah Jacqueline
KOCARNIK, Jonathan M.
PENBERTHY, Louise
AALI, Amirali
ABBAS, Qamar
Citação
LANCET, v.400, n.10352, p.563-591, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Findings Globally, in 2019, the risk factors included in this analysis accounted for 4.45 million (95% uncertainty interval 4.01-4.94) deaths and 105 million (95.0-116) DALYs for both sexes combined, representing 44.4% (41.3-48.4) of all cancer deaths and 42.0% (39.1-45.6) of all DALYs. There were 2.88 million (2.60-3.18) risk-attributable cancer deaths in males (50.6% [47.8-54.1] of all male cancer deaths) and 1.58 million (1.36-1.84) risk-attributable cancer deaths in females (36.3% [32.5-41.3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20.4% (12.6-28.4) and DALYs by 16.8% (8.8-25.0), with the greatest percentage increase in metabolic risks (34.7% [27.9-42.8] and 33.3% [25.8-42.0]). Interpretation The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/50355
Referências
  1. Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9
  2. Arnold M, 2018, INT J CANCER, V143, P1305, DOI 10.1002/ijc.31527
  3. Arnold M, 2015, LANCET ONCOL, V16, P36, DOI 10.1016/S1470-2045(14)71123-4
  4. Arriaga ME, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016178
  5. Bianchini F, 2002, LANCET ONCOL, V3, P565, DOI 10.1016/S1470-2045(02)00849-5
  6. Boffetta P, 2009, ANN ONCOL, V20, P550, DOI 10.1093/annonc/mdn597
  7. BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32
  8. Braveman P, 2014, PUBLIC HEALTH REP, V129, P19, DOI 10.1177/00333549141291S206
  9. Brown KF, 2018, BRIT J CANCER, V118, P1130, DOI 10.1038/s41416-018-0029-6
  10. Brundtland GH, 2000, JAMA-J AM MED ASSOC, V284, P750, DOI 10.1001/jama.284.6.750
  11. Danaei G, 2005, LANCET, V366, P1784, DOI 10.1016/S0140-6736(05)67725-2
  12. de Martel C, 2020, LANCET GLOB HEALTH, V8, pE180, DOI 10.1016/S2214-109X(19)30488-7
  13. DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192
  14. Evans J, 2013, ENVIRON RES, V120, P33, DOI 10.1016/j.envres.2012.08.005
  15. Flor LS, 2021, NAT MED, V27, P239, DOI 10.1038/s41591-020-01210-8
  16. Foreman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1
  17. *GBD 2019 RISK FAC, 2019, LANCET, V0396
  18. GBD 2019 Tobacco Collaborators, 2021, LANCET, V397, P2337, DOI 10.1016/S0140-6736(21)01169-7
  19. Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X
  20. Inoue M, 2012, ANN ONCOL, V23, P1362, DOI 10.1093/annonc/mdr437
  21. Islami F, 2018, CA-CANCER J CLIN, V68, P31, DOI 10.3322/caac.21440
  22. Katzmarzyk PT, 2009, J PHYS ACT HEALTH, V6, P269, DOI 10.1123/jpah.6.3.269
  23. Kocarnik JM, 2022, JAMA ONCOL, V8, P420, DOI 10.1001/jamaoncol.2021.6987
  24. Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
  25. Maringe C, 2020, LANCET ONCOL, V21, P1023, DOI 10.1016/S1470-2045(20)30388-0
  26. Marmot M, 2012, LANCET, V380, P1011, DOI 10.1016/S0140-6736(12)61228-8
  27. Monteiro CA, 2004, B WORLD HEALTH ORGAN, V82, P940
  28. Parkin DM, 2011, BRIT J CANCER, V105, pS77, DOI 10.1038/bjc.2011.489
  29. Poirier AE, 2019, PREV MED, V122, P140, DOI 10.1016/j.ypmed.2019.04.007
  30. Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857
  31. Pukkala E, 2009, ACTA ONCOL, V48, P646, DOI 10.1080/02841860902913546
  32. Richards M, 2020, NAT CANCER, V1, P565, DOI 10.1038/s43018-020-0074-y
  33. Rumgay H, 2021, LANCET ONCOL, V22, P1071, DOI 10.1016/S1470-2045(21)00279-5
  34. Schottenfeld D, 2013, ANNU REV PUBL HEALTH, V34, P97, DOI 10.1146/annurev-publhealth-031912-114350
  35. Sharpless NE, 2020, SCIENCE, V368, P1290, DOI 10.1126/science.abd3377
  36. Smoke T., 2004, IARC MONOGR EVAL CAR, V83, P1, DOI 10.5271/SJWEH.2890
  37. Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
  38. Szreter S, 2003, AM J PUBLIC HEALTH, V93, P421, DOI 10.2105/AJPH.93.3.421
  39. Takala J, 2015, IND HEALTH, V53, P307, DOI 10.2486/indhealth.53-307
  40. Wang HD, 2020, LANCET, V396, P1160, DOI 10.1016/S0140-6736(20)30977-6
  41. Wang JB, 2012, ANN ONCOL, V23, P2983, DOI 10.1093/annonc/mds139
  42. Whiteman DC, 2016, CANCER EPIDEMIOL, V44, P203, DOI 10.1016/j.canep.2016.06.013
  43. Whiteman DC, 2015, AUST NZ J PUBL HEAL, V39, P477, DOI 10.1111/1753-6405.12471
  44. WHO, SAFER INITIATIVE WOR
  45. WHO, 2017, TACKLING NCDS BEST B
  46. WHO, 2018, GLOB STAT REP ROAD S
  47. Winn AN, 2016, AM J PREV MED, V50, P241, DOI 10.1016/j.amepre.2015.08.009
  48. World Cancer Research Fund/American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/04
Artigos e Materiais de Revistas Científicas - ODS/03